| Dr John Michael Kasey, DO | |
|
613 23rd St Ste 130, Ashland, KY 41101-2876 | |
| (606) 329-9335 | |
| (606) 324-6383 |
| Full Name | Dr John Michael Kasey |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 19 Years |
| Location | 613 23rd St Ste 130, Ashland, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831371368 | NPI | - | NPPES |
| 3018157 | Medicaid | OH | |
| 7100099770 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 34.009922 (Ohio) | Secondary |
| 207RN0300X | Internal Medicine - Nephrology | 03237 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fmc - Ashland | Ashland, KY | Dialysis facility |
| Fmc - Ironton | Ironton, OH | Dialysis facility |
| King's Daughters' Medical Center | Ashland, KY | Hospital |
| Kings Daughters Medical Center Ohio | Portsmouth, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kings Daughters Medical Specialties Inc | 6103968029 | 328 |
| Kings Daughters Medical Specialties Inc | 6103968029 | 328 |
News Archive
Pharmasset, Inc. announced today that dosing has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 200mg QD and 400mg QD in combination with pegylated interferon alfa 2a and ribavirin, the current standard of care (SOC) in patients with HCV genotype 1 who have not been treated previously.
The ADEAGies Foundation, the philanthropic arm of the American Dental Education Association, has selected Columbia University's College of Dental Medicine for a 2014 William J. Gies Award, for outstanding achievement by an academic dental institution in support of dental education. The award recognizes CDM's Community DentCare program, which provides low- or no-cost dental care to children, adults, and seniors in Northern Manhattan and the Bronx.
HemaCare Corporation today announced an agreement with Dendreon Corporation to provide cellular collection services in Los Angeles and Maine for their new autologous cellular immunotherapy, PROVENGE® (sipuleucel-T). This personalized medicine is Dendreon's lead product and is the first autologous cellular immunotherapy specifically designed to engage patients' own immune systems to treat cancer.
UK diagnostics firm Salient Bio has announced the commercial roll out of its robotics driven COVID-19 mass testing platform.
› Verified 2 days ago
| Entity Name | Kings Daughters Medical Specialties Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710215736 PECOS PAC ID: 6103968029 Enrollment ID: O20100217000538 |
News Archive
Pharmasset, Inc. announced today that dosing has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 200mg QD and 400mg QD in combination with pegylated interferon alfa 2a and ribavirin, the current standard of care (SOC) in patients with HCV genotype 1 who have not been treated previously.
The ADEAGies Foundation, the philanthropic arm of the American Dental Education Association, has selected Columbia University's College of Dental Medicine for a 2014 William J. Gies Award, for outstanding achievement by an academic dental institution in support of dental education. The award recognizes CDM's Community DentCare program, which provides low- or no-cost dental care to children, adults, and seniors in Northern Manhattan and the Bronx.
HemaCare Corporation today announced an agreement with Dendreon Corporation to provide cellular collection services in Los Angeles and Maine for their new autologous cellular immunotherapy, PROVENGE® (sipuleucel-T). This personalized medicine is Dendreon's lead product and is the first autologous cellular immunotherapy specifically designed to engage patients' own immune systems to treat cancer.
UK diagnostics firm Salient Bio has announced the commercial roll out of its robotics driven COVID-19 mass testing platform.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Michael Kasey, DO Po Box 2379, Ashland, KY 41105-2379 Ph: (606) 408-6200 | Dr John Michael Kasey, DO 613 23rd St Ste 130, Ashland, KY 41101-2876 Ph: (606) 329-9335 |
News Archive
Pharmasset, Inc. announced today that dosing has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV). The trial will evaluate PSI-7977 200mg QD and 400mg QD in combination with pegylated interferon alfa 2a and ribavirin, the current standard of care (SOC) in patients with HCV genotype 1 who have not been treated previously.
The ADEAGies Foundation, the philanthropic arm of the American Dental Education Association, has selected Columbia University's College of Dental Medicine for a 2014 William J. Gies Award, for outstanding achievement by an academic dental institution in support of dental education. The award recognizes CDM's Community DentCare program, which provides low- or no-cost dental care to children, adults, and seniors in Northern Manhattan and the Bronx.
HemaCare Corporation today announced an agreement with Dendreon Corporation to provide cellular collection services in Los Angeles and Maine for their new autologous cellular immunotherapy, PROVENGE® (sipuleucel-T). This personalized medicine is Dendreon's lead product and is the first autologous cellular immunotherapy specifically designed to engage patients' own immune systems to treat cancer.
UK diagnostics firm Salient Bio has announced the commercial roll out of its robotics driven COVID-19 mass testing platform.
› Verified 2 days ago
Padma Venkatraman, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 101 Ashland Dr, Ashland, KY 41101 Phone: 606-324-1996 Fax: 606-833-2430 | |
Amr Idris, M.D. Nephrology Medicare: Medicare Enrolled Practice Location: 613 23rd St Ste 230, Ashland, KY 41101 Phone: 606-324-4745 Fax: 606-324-4941 | |
Paula K Larsen, MD Nephrology Medicare: Medicare Enrolled Practice Location: 1000 Ashland Dr Ste G1, Ashland, KY 41101 Phone: 606-408-4900 Fax: 606-408-6643 | |
Michael Don Canty, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 617 23rd St, Suite 11, Ashland, KY 41101 Phone: 606-324-3188 Fax: 606-329-2237 | |
Dr. Ryann Acquino Pangan, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 613 23rd St Ste 130, Ashland, KY 41101 Phone: 606-329-9335 Fax: 606-324-6383 | |
Dr. Francisco Fernandez-gonzalez, Nephrology Medicare: Accepting Medicare Assignments Practice Location: 613 23rd St Ste 310, Ashland, KY 41101 Phone: 606-833-2161 | |
Dr. Chad Jacob Tarabolous, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 617 23rd St, Suite 19, Ashland, KY 41101 Phone: 606-325-2221 Fax: 606-324-1326 |